MLTX — MoonLake Immunotherapeutics Income Statement
0.000.00%
Last trade - 00:00
- $2.86bn
- $2.32bn
- 30
- 30
- 64
- 36
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | 10-K | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Total Revenue | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Total Operating Expenses | 53.6 | 65.1 | 54.1 |
Operating Profit | -53.6 | -65.1 | -54.1 |
Other Net Non Operating Costs | |||
Net Income Before Taxes | -53.6 | -64.5 | -44 |
Provision for Income Taxes | |||
Net Income After Taxes | -53.6 | -64.5 | -44.1 |
Minority Interest | |||
Net Income Before Extraordinary Items | |||
Net Income | -53.6 | -50 | -36 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -53.6 | -50 | -36 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -1.45 | -1.7 | -0.733 |